Rare SNVs and indels were considered if they occurred in phenotypically relevant genes (i.e. LDLR, PCSK9, or APOB for patients with FH; LPL, APOA5, LMF1, GPIHBP1, or APOC2 for patients with hypertriglyceridemia) had a CADD PHRED-scaled score ≥ 10 plus a predicted deleterious or damaging outcomes by SIFT, PolyPhen2, or MutationTaster, and resulted in a change to the encoded protein’s amino acid sequence. The gene discussed is LPL; the disease is familial hyperaldosteronism.